Genomma Lab Internacional, SAB de CV (BMV: LABB), a Mexico-based over-the-counter pharmaceutical, generic drugs and personal care products company, announced on Thursday a cash dividend of MXN0.200000 per share on its common stock.
This represents a total amount of MXN200m.
The dividend is payable to shareholders of record of the applicable circulating shares at the close of business on 14 March 2025.
Genomma Lab intends to make dividend payments on a quarterly basis.
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo